Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pacritinib - CTI BioPharma

Drug Profile

Pacritinib - CTI BioPharma

Alternative Names: ENPAXIQ; Epjevy; ONX-0803; Pacritinib citrate - CTI BioPharma; Pacritinibum; SB-1518; VONJO

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator S*BIO
  • Developer Cardiff University; CTI BioPharma; National Cancer Research Institute; S*BIO
  • Class Antineoplastics; Aza compounds; Benzene derivatives; Ethers; Macrocyclic compounds; Polycyclic bridged compounds; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Interleukin-1 receptor-associated kinase inhibitors; Janus kinase 2 inhibitors; Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myelofibrosis
  • Phase II Graft-versus-host disease; VEXAS syndrome
  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Haematological disorders; Lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 12 May 2025 Phase-II clinical trials in VEXAS syndrome (Treatment-experienced) in Spain (PO) (NCT06782373)
  • 17 Jan 2025 Swedish Orphan Biovitrum plans a phase II trial for VEXAS Syndrome in USA, Canada, France, Germany, Italy, Spain and United Kingdom, in May 2025 (PO, Capsules) (NCT06782373, EUCT2024-516347-41-00, PAC601)
  • 17 Dec 2024 Pacritinib is still in phase-III clinical trials in Myelofibrosis in Belarus, Serbia, Georgia, Ukraine and Israel (NCT03165734)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top